ArticleInternational journal of nanomedicine2025
Blackberry-Like Doxorubicin Loaded Hyaluronic Acid/Zinc Phthalocyanine Loaded Mesoporous Silica Nanocomposites for Long-Term Tumor Photodynamic and Chemotherapy Synergistic Therapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The co-loading of zinc phthalocyanine (ZnPc) and doxorubicin (DOX) on a nanocarrier for tumor photodynamic therapy (PDT)-chemotherapy (CT) synergistic therapy is an effective approach. However, significant differences in water solubility between DOX and ZnPc hinder their high drug-loading content within a unified carrier. Additionally, DOX's systemic toxicity limits its therapeutic dosage, while low ZnPc loading shortens PDT duration, collectively restricting the efficacy of PDT and related synergistic therapy. This study aims to design a long-term PDT and CT synergistic therapy strategy to significantly improve the therapeutic effect and reduce the toxic side effects. Methods: We encapsulated ZnPc within biodegradable mesoporous silica nanoparticles (bMSN NPs) as the core, followed by electrostatic coating with tumor-targeting, DOX-loaded hyaluronic acid nanoparticles (DOX-HA NPs) to fabricate blackberry-like nanocomposites (DOX-HA/ZnPc-bMSN). In vitro and in vivo experiments determined tumor long-term PDT and CT synergistic therapy efficacy with DOX-HA/ZnPc-bMSN. Results: These nanocomposites achieved high ZnPc loading (DLC: 10.2% ± 1.6%) and efficient tumor accumulation, enabling prolonged systemic circulation (> 96 h) and sustained dual-drug release in vivo, realizing long-term photodynamic and CT synergistic therapy. In vitro studies showed a low combination index (CI = 0.26), with reactive oxygen species (ROS) production enhanced by 1.6-fold and 1.9-fold for ZnPc and DOX. The median lethal dose (LD50) of DOX-HA/ZnPc-bMSN nanocomposites (138.95 mg/kg) was 15.12 times higher than that of free DOX. Notably, in vivo studies demonstrated a 96.0% tumor inhibition rate has been achieved using ultralow doses of drugs (DOX: 0.2 mg/kg; ZnPc: 2 mg/kg). This long-term PDT and CT synergistic therapy elevated intracellular ROS levels, which not only induced apoptosis in tumor cells but also activated caspase-1, leading to direct GSDMD cleavage, GSDMD-N release, and pyroptotic tumor cell death. Conclusion: These nanocomposites dually trigger tumor cell apoptosis/pyroptosis, demonstrating potent therapeutic efficacy and safety for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.